A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice-Reference-Cited by-同舟云学术

A bioisostere of Dimebon/Latrepirdine delays the onset and slows the progression of pathology in FUS transgenic mice

Published:2021-03-23 Issue:7 Volume:27 Page:765-775
ISSN:1755-5930
Container-title:CNS Neuroscience & Therapeutics
language:en
Short-container-title:CNS Neurosci Ther

Author:

Chaprov Kirill¹,Rezvykh Alexander²³,Funikov Sergei²,Ivanova Tamara A.¹,Lysikova Ekaterina A.¹,Deykin Alexei V.⁴⁵,Kukharsky Michail S.¹⁶⁷,Yu. Aksinenko Alexey¹,Bachurin Sergey O.¹,Ninkina Natalia¹⁷^ORCID,Buchman Vladimir L.¹⁷^ORCID

Affiliation:

1. Institute of Physiologically Active Compounds Russian Academy of Science Chernogolovka Russia

2. Engelhardt Institute of Molecular Biology Russian Academy of Sciences Moscow Russia

3. Moscow Institute of Physics and Technology Dolgoprudny Russia

4. Center for Precision Genome Editing and Genetic Technologies for Biomedicine Institute of Gene Biology Russian Academy of Sciences Moscow Russia

5. Laboratory of Genome Editing for Veterinary and Biomedicine Belgorod State National Research University Belgorod region Russia

6. Pirogov Russian National Research Medical University Moscow Russia

7. School of Biosciences Cardiff University Cardiff UK

Funder

Motor Neurone Disease Association

Ministry of Science and Higher Education of the Russian Federation

Russian Foundation for Basic Research

Publisher

Wiley

Subject

Pharmacology (medical),Physiology (medical),Psychiatry and Mental health,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cns.13637

Reference66 articles.

1. Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics

2. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs

3. The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future

4. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches

5. Discovery of a Proneurogenic, Neuroprotective Chemical

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulation of ER-mitochondria tethering complex VAPB-PTPIP51: Novel therapeutic targets for aging-associated diseases;Ageing Research Reviews;2024-07

2. Lipopolysaccharide triggers exacerbated microglial activation, excessive cytokine release and behavioural disturbances in mice with truncated Fused-in-Sarcoma Protein (FUS);Brain, Behavior, & Immunity - Health;2023-11

3. Increasing brain N‐acetylneuraminic acid alleviates hydrocephalus‐induced neurological deficits;CNS Neuroscience & Therapeutics;2023-05-24

4. Cytoplasmic aggregation of mutant FUS causes multistep RNA splicing perturbations in the course of motor neuron pathology;Nucleic Acids Research;2023-04-28

5. Integrated multi-omic data analysis and validation with yeast model show oxidative phosphorylation modulates protein aggregation in amyotrophic lateral sclerosis;Journal of Biomolecular Structure and Dynamics;2022-06-24